Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1905 1
1949 2
1950 3
1951 1
1955 1
1969 1
1972 1
1974 1
1975 1
1976 2
1977 1
1978 2
1979 6
1980 4
1981 10
1982 7
1983 4
1984 6
1985 3
1986 6
1987 6
1988 9
1989 6
1990 8
1991 15
1992 11
1993 12
1994 10
1995 13
1996 12
1997 11
1998 7
1999 7
2000 10
2001 7
2002 10
2003 11
2004 10
2005 13
2006 9
2007 16
2008 19
2009 18
2010 31
2011 39
2012 38
2013 33
2014 56
2015 102
2016 92
2017 82
2018 77
2019 53
2020 83
2021 84
2022 89
2023 84
2024 34

Text availability

Article attribute

Article type

Publication date

Search Results

1,167 results

Results by year

Filters applied: . Clear all
Page 1
Dengue.
Simmons CP, Farrar JJ, Nguyen vV, Wills B. Simmons CP, et al. N Engl J Med. 2012 Apr 12;366(15):1423-32. doi: 10.1056/NEJMra1110265. N Engl J Med. 2012. PMID: 22494122 Free article. Review. No abstract available.
Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy.
Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E, Ungewiss J, Paschke M, Haase C, von Hacht JL, Kwan T, Lin KK, Lenore J, Harding TC, Xiao J, Simmons AD, Mohan AM, Beindorff N, Reineke U, Smerling C, Osterkamp F. Zboralski D, et al. Among authors: simmons ad. Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3651-3667. doi: 10.1007/s00259-022-05842-5. Epub 2022 May 24. Eur J Nucl Med Mol Imaging. 2022. PMID: 35608703 Free PMC article.
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Janjigian YY, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C, Chou JF, Segal MF, Simmons MZ, Momtaz P, Shcherba M, Ku GY, Zervoudakis A, Won ES, Kelsen DP, Ilson DH, Nagy RJ, Lanman RB, Ptashkin RN, Donoghue MTA, Capanu M, Taylor BS, Solit DB, Schultz N, Hechtman JF. Janjigian YY, et al. Among authors: simmons mz. Lancet Oncol. 2020 Jun;21(6):821-831. doi: 10.1016/S1470-2045(20)30169-8. Epub 2020 May 18. Lancet Oncol. 2020. PMID: 32437664 Free PMC article. Clinical Trial.
Patients were eligible to receive an initial induction cycle of 200 mg flat dose of intravenous pembrolizumab and 8 mg/kg loading dose of intravenous trastuzumab. For subsequent cycles, patients received 130 mg/m(2) of intravenous oxaliplatin or 80 mg/m(2) of cispla …
Patients were eligible to receive an initial induction cycle of 200 mg flat dose of intravenous pembrolizumab and 8 mg/kg loading dose of in …
Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir.
Ford ES, Simmons W, Karmarkar EN, Yoke LH, Braimah AB, Orozco JJ, Ghiuzeli CM, Barnhill S, Sack CL, Benditt JO, Roychoudhury P, Greninger AL, Shapiro AE, Hammond JL, Rusnak JM, Dolsten M, Boeckh M, Liu C, Cheng GS, Corey L. Ford ES, et al. Among authors: simmons w. Clin Infect Dis. 2023 Mar 4;76(5):926-929. doi: 10.1093/cid/ciac868. Clin Infect Dis. 2023. PMID: 36326680 Free PMC article.
In Vitro Matured Human Pluripotent Stem Cell-Derived Cardiomyocytes Form Grafts With Enhanced Structure and Function in Injured Hearts.
Dhahri W, Sadikov Valdman T, Wilkinson D, Pereira E, Ceylan E, Andharia N, Qiang B, Masoudpour H, Wulkan F, Quesnel E, Jiang W, Funakoshi S, Mazine A, Gomez-Garcia MJ, Latifi N, Jiang Y, Huszti E, Simmons CA, Keller G, Laflamme MA. Dhahri W, et al. Among authors: simmons ca. Circulation. 2022 May 3;145(18):1412-1426. doi: 10.1161/CIRCULATIONAHA.121.053563. Epub 2022 Jan 28. Circulation. 2022. PMID: 35089805
The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing.
Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, Banada PP, Deshpande S, Shenai S, Gall A, Glass J, Krieswirth B, Schumacher SG, Nabeta P, Tukvadze N, Rodrigues C, Skrahina A, Tagliani E, Cirillo DM, Davidow A, Denkinger CM, Persing D, Kwiatkowski R, Jones M, Alland D. Chakravorty S, et al. Among authors: simmons am. mBio. 2017 Aug 29;8(4):e00812-17. doi: 10.1128/mBio.00812-17. mBio. 2017. PMID: 28851844 Free PMC article.
For M. tuberculosis H37Rv, the LOD was 15.6 CFU/ml of sputum for Ultra versus 112.6 CFU/ml of sputum for Xpert, and for M. bovis BCG, it was 143.4 CFU/ml of sputum for Ultra versus 344 CFU/ml of sputum for Xpert. Ultra resulted in no false-positive RIF-R specimens, …
For M. tuberculosis H37Rv, the LOD was 15.6 CFU/ml of sputum for Ultra versus 112.6 CFU/ml of sputum for Xpert, and for M. bov …
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial.
Cytryn SL, Moy RH, Cowzer D, Shah RH, Chou JF, Joshi SS, Ku GY, Maron SB, Desai A, Yang J, Sugarman R, Rao D, Goldberg Z, Charalambous C, Lapshina M, Antoine A, Socolow F, Trivedi N, Capanu M, Gerdes H, Schattner MA, Simmons M, Lacouture ME, Paroder V, Tang LH, Shia J, Ilson DH, Solit DB, Berger MF, Janjigian YY. Cytryn SL, et al. Among authors: simmons m. Lancet Oncol. 2023 Oct;24(10):1073-1082. doi: 10.1016/S1470-2045(23)00358-3. Epub 2023 Sep 1. Lancet Oncol. 2023. PMID: 37666264 Clinical Trial.
Eligible patients had measurable disease or non-measurable disease that was evaluable (defined by Response Evaluation Criteria in Solid Tumours [RECIST] version 1.1) and Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received FOLFOX chemotherapy (fluoro …
Eligible patients had measurable disease or non-measurable disease that was evaluable (defined by Response Evaluation Criteria in Solid Tumo …
Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition.
Zboralski D, Osterkamp F, Christensen E, Bredenbeck A, Schumann A, Hoehne A, Schneider E, Paschke M, Ungewiss J, Haase C, Robillard L, Simmons AD, Harding TC, Nguyen M. Zboralski D, et al. Among authors: simmons ad. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2621-2635. doi: 10.1007/s00259-023-06211-6. Epub 2023 Apr 22. Eur J Nucl Med Mol Imaging. 2023. PMID: 37086273 Free PMC article.
Paraproteinemic neuropathies.
Raheja D, Specht C, Simmons Z. Raheja D, et al. Among authors: simmons z. Muscle Nerve. 2015 Jan;51(1):1-13. doi: 10.1002/mus.24471. Epub 2014 Nov 22. Muscle Nerve. 2015. PMID: 25288371 Review.
1,167 results